Zelboraf (vemurafenib) is a prescription medication used in the treatment of certain types of skin cancer, specifically late-stage melanoma or metastatic melanoma that cannot be removed by surgery. It is particularly effective in patients whose tumors have a mutation in the BRAF gene, a type of genetic alteration that can promote cancer growth. Zelboraf works by inhibiting the activity of the mutated BRAF protein, thereby slowing down or stopping the growth of the cancer cells. It is an oral medication, taken in pill form, and represents a targeted therapy approach, focusing on specific genetic components within cancer cells. As with any cancer treatment, it may cause side effects, and its use is typically managed by a healthcare professional specialized in oncology.